Eribol P, Uguz A K, Ulgen K O
Department of Chemical Engineering, Boğaziçi University , 34342 Bebek, Istanbul, Turkey.
Biomicrofluidics. 2016 Jan 28;10(1):011502. doi: 10.1063/1.4940886. eCollection 2016 Jan.
Microfluidics has been the focus of interest for the last two decades for all the advantages such as low chemical consumption, reduced analysis time, high throughput, better control of mass and heat transfer, downsizing a bench-top laboratory to a chip, i.e., lab-on-a-chip, and many others it has offered. Microfluidic technology quickly found applications in the pharmaceutical industry, which demands working with leading edge scientific and technological breakthroughs, as drug screening and commercialization are very long and expensive processes and require many tests due to unpredictable results. This review paper is on drug candidate screening methods with microfluidic technology and focuses specifically on fabrication techniques and materials for the microchip, types of flow such as continuous or discrete and their advantages, determination of kinetic parameters and their comparison with conventional systems, assessment of toxicities and cytotoxicities, concentration generations for high throughput, and the computational methods that were employed. An important conclusion of this review is that even though microfluidic technology has been in this field for around 20 years there is still room for research and development, as this cutting edge technology requires ingenuity to design and find solutions for each individual case. Recent extensions of these microsystems are microengineered organs-on-chips and organ arrays.
在过去二十年里,微流控技术因其具有诸多优势而备受关注,比如化学试剂消耗低、分析时间缩短、高通量、对质量和热传递的更好控制、将台式实验室缩小至芯片(即芯片实验室)以及它所具备的许多其他优势。微流控技术很快就在制药行业得到了应用,制药行业需要借助前沿的科技突破开展工作,因为药物筛选和商业化过程漫长且成本高昂,而且由于结果不可预测还需要进行大量测试。这篇综述论文围绕采用微流控技术的候选药物筛选方法展开,特别聚焦于微芯片的制造技术和材料、连续或离散等流动类型及其优势、动力学参数的测定以及与传统系统的比较、毒性和细胞毒性评估、高通量浓度生成以及所采用的计算方法。这篇综述的一个重要结论是,尽管微流控技术在该领域已经应用了约20年,但仍有研发空间,因为这项前沿技术需要创造性思维来为每个具体案例进行设计并找到解决方案。这些微系统的最新扩展是微工程化的芯片上器官和器官阵列。